CABATEN Trial Cabozantinib+Atezolizumab in Endocrin Cancers CABATEN trial tested cabozantinib plus atezolizumab in rare endocrine cancers, showing durable responses in ATC and ACC.

New Paper Alert: CABATEN Trial Results- Cabozantinib and Atezolizumab Show Durable Responses in Rare Endocrine Cancers

oncodaily.com/new-paper-al...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CABATEN #Cabozantinib #Atezolizumab #EndocrineCancers